Skip Navigation
Skip to contents

JPMPH : Journal of Preventive Medicine and Public Health

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "Hae-Young Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Association Between Angiotensin II Receptor Blockers and the Risk of Lung Cancer Among Patients With Hypertension From the Korean National Health Insurance Service-National Health Screening Cohort
Sungji Moon, Hae-Young Lee, Jieun Jang, Sue K. Park
J Prev Med Public Health. 2020;53(6):476-486.   Published online November 3, 2020
DOI: https://doi.org/10.3961/jpmph.20.405
  • 4,657 View
  • 152 Download
  • 5 Crossref
AbstractAbstract PDFSupplementary Material
Objectives
The objective of this study was to estimate the risk of lung cancer in relation to angiotensin II receptor blocker (ARB) use among patients with hypertension from the Korean National Health Insurance Service-National Health Screening Cohort. Methods: We conducted a retrospective cohort study of patients with hypertension who started to take antihypertensive medications and had a treatment period of at least 6 months. We calculated the weighted hazard ratios (HRs) and their 95% confidence intervals (CIs) of lung cancer associated with ARB use compared with calcium channel blocker (CCB) use using inverse probability treatment weighting. Results: Among a total of 60 469 subjects with a median follow-up time of 7.8 years, 476 cases of lung cancer were identified. ARB use had a protective effect on lung cancer compared with CCB use (HR, 0.75; 95% CI, 0.59 to 0.96). Consistent findings were found in analyses considering patients who changed or discontinued their medication (HR, 0.50; 95% CI, 0.32 to 0.77), as well as for women (HR, 0.56; 95% CI, 0.34 to 0.93), patients without chronic obstructive pulmonary disease (HR, 0.75; 95% CI, 0.56 to 1.00), never-smokers (HR, 0.64; 95% CI, 0.42 to 0.99), and non-drinkers (HR, 0.69; 95% CI, 0.49 to 0.97). In analyses with different comparison antihypertensive medications, the overall protective effects of ARBs on lung cancer risk remained consistent. Conclusions: The results of the present study suggest that ARBs could decrease the risk of lung cancer. More evidence is needed to establish the causal effect of ARBs on the incidence of lung cancer.
Summary

Citations

Citations to this article as recorded by  
  • Association between Statins and Incidence of Cancer in Patients with Dyslipidemia Using Large-Scale Health Insurance Claims Data
    Ayako Maeda-Minami, Masayuki Takagi, Yasunari Mano, Hideki Ishikawa, Yutaka Matsuyama, Michihiro Mutoh
    Cancer Prevention Research.2023; 16(1): 37.     CrossRef
  • Angiotensin Receptor Blocker Associated with a Decreased Risk of Lung Cancer: An Updated Meta-Analysis
    Zexu Wang, Lingyun Wei, Cheng Yin, Wang Li, Bing Wan
    Journal of Personalized Medicine.2023; 13(2): 243.     CrossRef
  • The association between angiotensin receptor blockers and lung, bladder, and colon cancer development: A 10-year multicentric retrospective Lebanese study
    Yara G. Dagher, Sandra El Helou, Karen G. Haifa, Issam G. Chalhoub, Rita T. Boulos, Bachir Atallah, Fadi Nasr, Issam Kassab, Mirna N. Chahine
    Medicine.2023; 102(36): e34901.     CrossRef
  • Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers and Cancer Risk: An Updated Meta-Analysis of Observational Studies
    Kayeong Shin, Jiwoo Yang, Yeuni Yu, Eunjeong Son, Kihun Kim, Yun Hak Kim
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • The Effect of Local Renin Angiotensin System in the Common Types of Cancer
    Moudhi Almutlaq, Abir Abdullah Alamro, Hassan S. Alamri, Amani Ahmed Alghamdi, Tlili Barhoumi
    Frontiers in Endocrinology.2021;[Epub]     CrossRef

JPMPH : Journal of Preventive Medicine and Public Health